Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan by Allais, Gianni et al.
SYMPOSIUM: MENSTRUAL MIGRAINE
Evolution of migraine-associated symptoms in menstrually related
migraine following symptomatic treatment with almotriptan
Gianni Allais • Giancarlo Acuto • Chiara Benedetto • Giovanni D’Andrea •
Licia Grazzi • Gian Camillo Manzoni • Franca Moschiano • Florindo d’Onofrio •
Fabio Valguarnera • Gennaro Bussone
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract In addition to headache, migraine is charac-
terized by a series of symptoms that negatively affects the
quality of life of patients. Generally, these are represented
by nausea, vomiting, photophobia, phonophobia and
osmophobia, with a cumulative percentage of the onset in
about 90% of the patients. From this point of view, men-
strually related migraine—a particularly difﬁcult-to-treat
form of primary headache—is no different from other
forms of migraine. Symptomatic treatment should therefore
be evaluated not only in terms of headache relief, but also
by considering its effect on these migraine-associated
symptoms (MAS). Starting from the data collected in a
recently completed multicentre, randomized, double-blind,
placebo-controlled, cross-over study with almotriptan in
menstrually related migraine, an analysis of the effect of
this drug on the evolution of MAS was performed. Data
suggest that almotriptan shows excellent efﬁcacy on MAS
in comparison to the placebo, with a signiﬁcant reduction
in the percentages of suffering patients over a 2-h period of
time.
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Introduction
Migraine is much more than just headache since it is
characterized by a series of symptoms that are often par-
ticularly severe and disturbing for the patients and which
greatly contribute to worsening their quality of life. The
most common migraine-associated symptoms (MAS) are
nausea, vomiting, photophobia, phonophobia and osmo-
phobia, with a cumulative percentage of the onset in about
90% of the patients.
In menstrually related migraine (MRM), a particularly
difﬁcult-to-treat form of primary headache, MAS are also
present in percentages similar to the other forms of
migraine (non-MRM). Data in recent literature report that
in MRM versus non-MRM, pre-treatment nausea is present
in 40.4 versus 33.4% of attacks, phonophobia in 71.3
versus 75.4% of attacks and photophobia in 84.0 versus
78.9% of attacks, respectively [1].
MRM is a common form of migraine affecting more
than 50% of female migraineurs [2]. Population-based
studies indicate that this type of migraine, which occurs
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aura and is signiﬁcantly more likely (but not exclusively) to
occur on the 2 days before and on the ﬁrst 3 days of
menses. Only a small percentage of female migraineurs
(7–12%) have migraine attacks exclusively occurring in this
period, a condition known as ‘‘pure menstrual migraine’’.
The various drugs used to treat ‘ordinary’ migraine may
be prescribed for MRM, but triptans—selective 5-hydrox-
ytriptamine (5-HT) 1B/1D receptor agonists, which are
considered the most effective speciﬁc acute anti-migraine
medications—are preferable for MRM in view of its dif-
ﬁcult-to-treat nature [2, 3].
Almotriptan is one of the most recent selective 5-HT
1B/1D receptor agonists successfully used for the acute
treatment of migraine. It is rapidly absorbed, with very
good oral bioavailability (80%), and at the usual dose of
12.5 mg is at least as or even more effective than suma-
triptan 100 mg and has a signiﬁcantly better tolerability
proﬁle [4].
A placebo-controlled randomized study with almotrip-
tan in MRM was recently concluded and data relevant to
the number of patients reporting MAS were therefore
available for a separate analysis. It is interesting to evaluate
the effects of the symptomatic treatment of the migraine
attack more closely, not only as far as pain relief is con-
cerned, but also in terms of MAS evolution, particularly if
patients are suffering from MRM.
The aim of this analysis is to show and discuss the
evolution of nausea, vomiting, photophobia, phonophobia
and osmophobia in MRM patients following treatment with
almotriptan 12.5 mg or placebo.
Methods
The original trial was a multicentre, randomized, double-
blind, placebo-controlled, cross-over study that was fol-
lowed by an open phase. In the double-blind period, two
single menstrual migraine attacks per menstrual cycle were
treated with almotriptan or placebo (and vice versa). In the
open phase, two additional single attacks (3rd and 4th) per
menstrual cycle were treated with almotriptan.
The primary objective of the original study consisted
in proving the effectiveness (superiority hypothesis) of
almotriptan versus placebo by testing the percentages of
patients pain free at 2 h (primary study end point) fol-
lowing drug intake.
Patients were provided with a diary card to record their
migraine attacks for each menstrual cycle under consider-
ation. In particular, at 0, 15, 30, 60, 120 min and 24 h after
drug intake, the presence or absence of nausea, vomiting,
phonophobia, photophobia and osmophobia were recorded
along with the intensity of headache pain and other
parameters.
Treatment
Almotriptan or matching placebo was self-administered at
the onset of the ﬁrst menstrual migraine attack occurring
during the speciﬁed window (day -2t o?3) of the men-
strual cycle. One single menstrual migraine attack per
menstrual cycle was treated in four different menstrual
cycles. One out of the ﬁrst two of the four attacks was
placebo-treated. Each attack was treated with one single
tablet.
Statistical analysis
For each symptom and for each scheduled time, the per-
centage of patients was analyzed using a generalized linear
model implemented with binomial distribution, log-link
function and generalized estimating equations (GEE).
Results were reported as risk ratio (RR) with associated
95% CL and two-tailed p values. The main analysis was
performed on the modiﬁed intention-to-treat population
(mITT), deﬁned as all randomized patients who received at
least one dose of study medication and in whom the
evaluation of the primary outcome, at both the ﬁrst and the
second period of the double-blind phase, was available.
Results
Following a screening period, 147 outpatient women aged
18–50 and suffering from MRM without aura (IHS criteria)
were randomized: 74 to almotriptan-placebo and 73 to
placebo-almotriptan; 122 patients completed the double-
blind phase (mITT) and 105 completed the additional open
follow-up phase (two further attacks).
Patient disposition is summarized in Table 1.
All patients were Caucasian and no statistically signiﬁ-
cant differences were found when comparing age, height
and weight (Table 2).
In general, descriptive statistics highlighted that: (a)
about half of the migraine attacks occurred between the
ﬁrst and second day of the menstrual period, (b) moderate/
severe headache occurred in 55–60% of migraine attacks
and (c) an association with other symptoms (nausea,
vomiting, etc.) was present in about 90% of patients.
Around 30% of the patients were able to treat migraine
attack during its mild phase.
The study achieved its main objective of demonstrating
the superiority of almotriptan compared to placebo in
terms of percentage of patients being pain free at 2 h.
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adverse events compared to placebo.
The results on MAS appear to be consistent with the
migraine pain scale results, with sparse statistically sig-
niﬁcant differences in favor of almotriptan (Fig. 1a–e). The
principal ﬁndings are summarized below.
Nausea
Double-blind phase
The percentages of patients that experienced nausea varied,
respectively, from 43.4% (almotriptan) and 41% (placebo)
at 15 min with a RR of 1.04 (95% CI; 0.86–1.27;
p value = 0.6609) to 19% (almotriptan) and 36.7%
(placebo) at 2 h with a RR of 0.52 (95% CI; 0.36–0.76;
p value = 0.0007) and to 10.1% (almotriptan) and 19.1%
(placebo) at 24 h with a RR of 0.52 (95% CI; 0.28–0.96;
p value = 0.0354).
Follow-up phase
The percentages of patients that experienced nausea var-
ied, respectively, from 41.8% (attack no. 3) and 36.2%
(attack no. 4) at 15 min to 14.5% (attack no. 3) and 14.4%
(attack no. 4) at 2 h and to 10.5% (attack no. 3) and
11.9% (attack no. 4) at 24 h.
Vomiting
Double-blind phase
The percentages of patients that experienced vomiting
varied, respectively, from 3.3% (almotriptan) and 4.9%
(placebo) at 15 min with a RR of 0.58 (95% CI; 0.16–2.13;
p value = 0.4100) to 4.1% (almotriptan) and 9.2% (pla-
cebo) at 2 h with a RR of 0.44 (95% CI; 0.18–1.13;
p value = 0.0876) and to 2.5% (almotriptan) and 0.9%
(placebo) at 24 h with a RR not estimated.
Follow-up phase
The percentages of patients that experienced vomiting
varied, respectively, from 6.4% (attack no. 3) and 1.9%
(attack no. 4) at 15 min to 2.7% (attack no. 3) and 1%
(attack no. 4) at 2 h and to 1% (attack no. 3) and 0% (attack
no. 4) at 24 h.
Table 1 Characteristics of study population
Study population Almotriptan–placebo
(n = 74)
Placebo–almotriptan
(n = 73)
All patients
(n = 147)
ITT population (all random pts) 74 (100%) 73 (100%) 147 (100%)
No study medication intake 7 (9.5%) 8 (11%) 15 (10.2%)
Safety population 67 (90.5%) 65 (89%) 132 (89.8%)
No available data in DB phase for primary outcome 4 (5.4%) 6 (8.2%) 10 (6.8%)
Modiﬁed ITT population 63 (85.1%) 59 (80.8%) 122 (83%)
Table 2 Major demographic and background characteristics by treatment group–ITT population
Variable Almotriptan–placebo
(n = 74)
Placebo–almotriptan
(n = 73)
All patients
(n = 147)
p value
Age (years)
Mean ± SD (N) 35.17 ± 8.11 (74) 34.66 ± 7.93 (73) 34.92 ± 7.99 (147) 0.6995
Median (min–max) 35.54 (20.65–49.68) 35.09 (17.04–52.05) 35.34 (17.04–52.05)
Height
Mean ± SD (N) 1.65 ± 0.05 (74) 1.63 ± 0.05 (73) 1.64 ± 0.05 (147) 0.0654
Median (min–max) 1.65 (1.53–1.8) 1.63 (1.45–1.76) 1.65 (1.45–1.8)
Weight
Mean ± SD (N) 59.93 ± 9.43 (74) 57.85 ± 8.8 (73) 58.9 ± 9.15 (147) 0.1687
Median (min–max) 60 (43–80) 56 (46–88) 58 (43–88)
White/Caucasian race 74 (100%) 73 (100%) 147 (100%) ND
Has the patient suffered from a migraine attack
occurred on day -2t o?3 of menstruation
in at least two of three preceding months? yes
74 (100%) 73 (100%) 147 (100%) ND
The patient has regular menstrual cycles 74 (100%) 73 (100%) 147 (100%) ND
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Double-blind phase
The percentages of patients that experienced photophobia
varied, respectively, from 58.2% (almotriptan) and 60.7%
(placebo) at 15 min with a RR of 0.96 (95% CI; 0.83–1.10;
p value = 0.5421) to 33.1% (almotriptan) and 49.2%
(placebo) at 2 h with a RR of 0.67 (95% CI; 0.50–0.90;
p value = 0.0083) and to 10.9% (almotriptan) and 22.6%
(placebo) at 24 h with a RR of 0.42 (95% CI; 0.21–0.80;
p value = 0.0092).
Follow-up phase
The percentages of patients that experienced photophobia
varied, respectively, from 60% (attack no. 3) and 59%
(attack no. 4) at 15 min to 24.5% (attack no. 3) and
21.2% (attack no. 4) at 2 h and to 12.4% (attack no. 3) and
15.8% (attack no. 4) at 24 h.
Phonophobia
Double-blind phase
The percentages of patients that experienced phonophobia
varied, respectively, from 59% (almotriptan) and 54.9%
(placebo) at 15 min with a RR of 1.07 (95% CI; 0.93–1.24;
p value = 0.3288) to 30.6% (almotriptan) and 41.7%
(placebo) at 2 h with a RR of 0.73 (95% CI; 0.53–1.01;
p value = 0.0566) and to 10.1% (almotriptan) and 18.3%
(placebo) at 24 h with a RR of 0.48 (95% CI; 0.24–0.95;
p value = 0.0347).
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Fig. 1 The evolution of migraine-associated symptoms
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The percentages of patients that experienced phonophobia
varied, respectively, from 50% (attack no. 3) and 48.6%
(attack no. 4) at 15 min to 18.2% (attack no. 3) and 20.2%
(attack no. 4) at 2 h and to 11.4% (attack no. 3) and
13.9% (attack no. 4) at 24 h.
Osmophobia
Double-blind phase
The percentages of patients that experienced osmophobia
varied, respectively, from 20.5% (almotriptan) and 15.6%
(placebo) at 15 min with a RR of 1.32 (95% CI; 0.92–1.89;
p value = 0.1375) to 12.4% (almotriptan) and 12.5%
(placebo) at 2 h with a RR of 0.99 (95% CI; 0.55–1.81;
p value = 0.9856) and to 4.2% (almotriptan) and 6.1%
(placebo) at 24 h with a RR of 0.62 (95% CI; 0.19–2.05;
p value = 0.4340).
Follow-up phase
The percentages of patients that experienced osmophobia
varied, respectively, from 15.5% (attack no. 3) and 12.4%
(attack no. 4) at 15 min to 1.8% (attack no. 3) and 3.8%
(attack no. 4) at 2 h and to 4.8% (attack no. 3) and
4% (attack no. 4) at 24 h.
Conclusions
MRM is particularly difﬁcult to treat and the presence of
associated symptoms signiﬁcantly worsens patient func-
tioning. This is also highlighted by the correlation found
between the severity of MAS (especially nausea, photo-
phobia and phonophobia) and impaired functioning. In
fact, quality of life is critically lowered by the presence of
severe MAS, and consequently symptomatic treatment
should also be carefully evaluated in terms of its efﬁcacy in
affecting MAS.
Almotriptan has proven to be effective in the control of
migraine pain in menstrual migraine [5]. The present study
demonstrated that almotriptan in MRM treatment showed
excellent efﬁcacy on MAS in comparison to placebo, with
a signiﬁcant reduction in the percentages of suffering
patients over a 2-h period of time. These positive data were
also conﬁrmed during the open follow-up phase.
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